Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2026-04-02 Capital/Financing Update
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
424B4 - VivoSim Labs, INC. (0001497253) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(4) for a public offering of common stock, pre-funded warrants, and common warrants. It includes detailed terms of the offering, pricing, tranches, placement agent fees, and risk factors. This type of document is related to capital raising activities and financing transactions. It is not an annual report, earnings release, or any other type of report but specifically a disclosure document for a securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus, not just an announcement or a brief summary.
2026-04-02 English
S-1/A - VivoSim Labs, INC. (0001497253) (Filer)
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC by VivoSim Labs, Inc. It is a registration statement under the Securities Act of 1933, related to a public offering of common stock and warrants. The text includes detailed information about the offering, terms of the securities, placement agent, and offering conditions. This type of filing is a capital raising document, specifically a registration statement for securities issuance. It is not an annual report, earnings release, or any other report type. The Form S-1 registration statement and its amendments are classified under Capital/Financing Update filings, as they relate to fundraising and capital structure changes.
2026-03-31 English
S-1 - VivoSim Labs, INC. (0001497253) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a filing fee calculation table for an S-1 registration statement, which is a form used by companies to register securities for public offering. It details the types of securities, fee calculations, and registration fees due. This type of document is related to capital raising activities and financing. It is not an annual report, earnings release, or any other financial report but rather a capital/financing update related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not merely an announcement but a substantive filing related to financing.
2026-03-27 English
10-Q Filing
Interim / Quarterly Report Q3 2025
2026-02-11 English
4 Filing
Director's Dealing
2026-01-29 English
4 Filing
Director's Dealing
2026-01-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.